<DOC>
	<DOCNO>NCT00005622</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor bone marrow transplant help stop growth cancer cell . It also help stop patient 's immune system reject donor 's stem cell . When stem cell relate unrelated donor , closely match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This phase II trial study well donor bone marrow transplant work treat patient leukemia , lymphoma , nonmalignant hematologic disorder .</brief_summary>
	<brief_title>Donor Bone Marrow Transplant Treating Patients With Leukemia , Lymphoma , Nonmalignant Hematologic Disorders</brief_title>
	<detailed_description>OBJECTIVES : - Determine survival allogeneic bone marrow transplantation use closely match relate unrelated donor patient malignant nonmalignant hematological disorder . - Determine incidence severity acute chronic graft versus host disease treatment regimen patient . - Determine relapse rate treatment regimen patient malignant disorder . - Determine incidence severity infectious complication associate treatment regimen patient . OUTLINE : Patients receive cyclophosphamide IV 1 hour day -6 -5 , total body radiotherapy day -3 0 , allogeneic bone marrow transplantation day 0 . Patients acute lymphocytic leukemia ( ALL ) receive intrathecal methotrexate beginning study . If CNS involvement document , patient receive second dose methotrexate 48 hour later follow oral leucovorin calcium every 6 hour 4 dos . Patients ALL and/or CNS involvement receive intrathecal methotrexate every week 12 week transplant . Patients prior CNS involvement receive radiotherapy 2.5 week prior transplant . Patients ALL receive total body radiotherapy 5 consecutive day prior transplant . Patients follow week 3 month , monthly 1 year . PROJECTED ACCRUAL : A total 30 patient accrue study 6 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one following : Acute lymphocytic leukemia ( ALL ) : Complete remission ( CR ) 1 high risk define overt CNS involvement poor cytogenetics ( addition , deletion , translocation , multiple abnormality ) CR2 Induction failure Relapse patient least 10 % marrow blast undergo least one reinduction attempt Acute myelogenous leukemia ( AML ) : CR1 high risk define poor cytogenetics ( deletion , addition , multiple abnormality ) CR2 Induction failure Relapse patient least 10 % marrow blast undergo least one reinduction attempt Chronic myelogenous leukemia ( CML ) : Chronic phase ( CP ) 1 Accelerated phase/CP2 patient blast phase must undergo treatment achieve second chronic phase prior transplant Chronic lymphocytic leukemia ( CLL ) : Relapse stage ; must receive 3 prior regimen Multiple myeloma : At diagnosis primary refractory Relapse ( 2 ) sensitive disease Plasma cell leukemia Inability achieve complete remission autologous transplant ( old 40 ) Myelodysplasia subtypes Myeloproliferative disorder patient poor response medical therapy cytogenetic abnormality Severe aplastic anemia ( SAA ) : Very SAA diagnosis SAA induction therapy Donors must phenotypic ( 6 6 ) match one antigen ( A B ) mismatch PATIENT CHARACTERISTICS : Age : 15 50 Performance status : Karnofsky 80100 % Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Bilirubin great 2.0 mg/dL SGOT SGPT great 3 time normal PT/PTT normal Renal : Creatinine great 2.0 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : Left ventricular ejection fraction least 45 % No myocardial infarction within past 6 month No uncontrolled arrhythmia Pulmonary : FEV1 least 50 % DLCO least 50 % predict Other : No active serious infection HIV negative Not pregnant nursing No uncontrolled diabetes mellitus thyroid disease PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>polycythemia vera</keyword>
	<keyword>primary myelofibrosis</keyword>
	<keyword>essential thrombocythemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>